Researchers at Australia’s national science agency, CSIRO, have developed a technique that protects vaccines at temperatures of up to 37 degrees Celsius: addressing the challenge of transporting vaccines to rural communities.
The European Medicines Agency (EMA) recommended 92 medicines for marketing authorization in 2021: 54 of which had a new active substance which had never been authorized in the EU before.
A California based biotech has tripled its capacity to manufacture GMP grade induced pluripotent stem cells (iPSC) space through the expansion of its contract development and manufacturing (CDMO) facility.
The initiative is seeking proposals from final year MD, PhD students and postdoctoral researchers in relation to drug discovery and development across AstraZeneca’s core disease areas.
Nutcracker Therapeutics, a biotech developing RNA therapeutics using its proprietary biochip-based manufacturing platform, has raised $167m in Series C financing: allowing it to expand and advance its pipeline of mRNA medicines for cancer and further...
Biogen has announced new Phase 3 data showing that, after nearly 2.5 years of treatment, Aduhelm continued to reduce two key Alzheimer’s disease pathologies.
The selected companies, the inaugural cohort for MassBioDrive, get to participate in an eight-week program focused on growing businesses and advancing breakthrough science.
Novartis continues down the third-party manufacturing route, as it secures an agreement with Carisma Therapeutics, a firm developing a cell therapy platform focused on engineered macrophage-based therapeutics.
Sanofi and Blackstone today announced a strategic, risk-sharing collaboration under which funds managed by Blackstone Life Sciences will contribute up to €300m ($329m) to accelerate development for subcutaneous formulation and delivery of anti-CD38 antibody...
Pfizer Inc says it will maintain its supply of medicines to Russia but it will not initiate new clinical trials in the country, while Bayer is suspending investment projects and new-business development in that market.
Adiso Therapeutics has emerged from stealth mode with a pipeline of therapies including live biotherapeutic (LBP) strains focused on tackling inflammatory diseases.
Vibalogics, which was recently acquired by Swedish company, Recipharm, says the completion of its expansion project at its facility in Germany boosts capacity and further enhances its flexibility, minimizing time to clinic for customers.
Novo Nordisk is expanding its existing collaborative research partnership in oral drug delivery technologies with the Massachusetts Institute of Technology (MIT) and Brigham and Women’s Hospital (BWH).
Finnish company, Biovian Oy, has been engaged by a South Korea biotechnology company to carry out process development and manufacturing of an AAV-based innovative drug candidate.
Flow Eighteen38, a protein sciences division created to facilitate and accelerate antibody characterization and protein purification projects, has announced a €5m ($5.58m) investment into its protein production and biophysical characterization capabilities...
mRNA pioneer Moderna has entered into a Memorandum of Understanding with the Government of the Republic of Kenya to establish an mRNA manufacturing facility in the country.
Biogen has started the process of laying off some US staff, following the less than optimal rollout of its Alzheimer’s disease drug, approved by the FDA in June 2021.
Charles River recently announced the expansion of its plasmid DNA and viral vector development and manufacturing capabilities in Europe; it says the move is to support the growing need of customers and to safeguard future supply.
Clinical Research Organization Veristat has acquired SLF (Solutions for Life Sciences): adding capabilities to support biotech, pharmaceutical and medtech companies.
WuXi STA says its drug product facility in Wuxi City, China has successfully passed its first pre-approval inspection (PAI) and received the GMP compliance certificate from the European Medicines Agency (EMA).
mRNA pioneer Moderna will establish an Enterprise Solutions Hub in Atlanta: which will host finance, human resources, procurement and digital functions.
The US Health and Human Services (HHS) Office of Inspector General (OIG) is to launch a study on the use and spending trends for biosimilars in Medicare Part B.
Stevenage Bioscience Catalyst (SBC) has launched an accelerator program for biotech start-ups focusing on data-enabled drug discovery, genomics and advanced therapies: aiming to give such companies the skills they need to get potential new drugs and therapies...
The authors of clinical data published in Nature Medicine this week said the findings indicate the use of a live biotherapeutic (LBP) with immunotherapy medicine can improve survival in patients with metastatic kidney cancer.
Celyad Oncology has decided to voluntarily pause dosing and enrollment of patients in the CYAD-101-002 trial in order to investigate reports of two patient deaths.
A consortium of nine development and finance institutions have announced a partnership with South African vaccine manufacturer Biovac to support its manufacturing expansion.
Alexion, AstraZeneca’s Rare Disease group, has closed an exclusive global collaboration and licence agreement with Neurimmune AG for NI006, an investigational human monoclonal antibody for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM).
A global biomanufacturing training hub will be established in Korea to serve low- and middle-income countries wishing to produce biologicals such as vaccines, insulin, monoclonal antibodies and cancer treatments.
Moderna and Thermo Fisher Scientific have announced a 15-year strategic collaboration agreement to enable dedicated large-scale manufacturing of COVID-19 vaccine Spikevax in the US, as well as other investigational mRNA vaccines and therapies.
TargED Biopharmaceuticals, a spin-off from the University Medical Center Utrecht that is developing therapies to improve treatment of thrombosis, has raised Series A financing of €39m (US$44.1m)
Semarion Ltd, a University of Cambridge spin-out company combining materials engineering and cell biology to tackle unmet drug screening needs, has just closed a £2.14m (US$2.89m) seed funding round.
Releasing data from both Phase 3 and booster trials, Sanofi and GSK have announced they will submit the results as the basis for regulatory applications for their COVID-19 vaccine.
Valneva has been awarded up to £20m ($27m) in R&D funding from Scottish Enterprise: which will be used to revive its plans to increase vaccine manufacturing in Scotland.
Moderna has initiated the Phase 3 portion of its pivotal respiratory syncytial virus (RSV) vaccine trial: looking towards its ultimate goal to combine the vaccine with its COVID-19 and flu boosters into a single dose booster.
4D Pharma says the US Food and Drug Administration (FDA) has cleared its IND application for the first in-human trial to use Live Biotherapeutics (LBPs) for the treatment of Parkinson’s disease.
PerkinElmer’s Sirion Biotech business is teaming up with the Centre for Genomic Regulation (CGR) to jointly develop new generation adeno-associated virus (AAV) vectors for type 1 and type 2 diabetes gene therapy in the pancreas.
Moderna is expanding its mRNA pipeline with three new development programs: with vaccine candidates against herpes simplex virus (HSV), varicella-zoster virus (VSV) and a new checkpoint cancer vaccine.
